Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03419364 · ClinicalTrials.gov registry record · Phase 2
Study of Nicotinamide in Early Onset Preeclampsia
A Phase 2 study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT03419364 is a Phase 2 study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 23 participants.
The verdict
NCT03419364, a Phase 2 study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
Phase II Study of 2.5 gm of nicotinamide, given daily in 3 divided doses, to measure effect on maternal blood pressure in women with early onset preeclampsia and to determine peak and trough levels of nicotinamide. We will compare peak and trough levels in healthy non-pregnant and healthy pregnant participants.
Interventions
- DRUG nicotinamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2017-11-01 |
| Est. Completion | 2021-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03419364
The ClinicalTrials.gov registry entry for NCT03419364 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which nicotinamide is the first listed.
NCT03419364 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03419364 about?
NCT03419364 is a clinical study titled "Study of Nicotinamide in Early Onset Preeclampsia". Phase II Study of 2.5 gm of nicotinamide, given daily in 3 divided doses, to measure effect on maternal blood pressure in women with early onset preeclampsia and to determine peak and trough levels of nicotinamide. We will compare peak and trough levels in healthy non-pregnant and healthy pregnant p...
What is the current status of trial NCT03419364?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2017-11-01. Estimated completion is 2021-08-31.
What interventions are being tested in trial NCT03419364?
The interventions under investigation include: nicotinamide (DRUG).
Who is sponsoring clinical trial NCT03419364?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.